It is with profound sadness that we acknowledge the passing of Lady Amanda Feilding, Founder and Director of the Beckley Foundation and Co-Founder of Beckley Psytech, aged 82.
Amanda’s life was dedicated to advancing the understanding of consciousness and advocating for progressive drug policy reform. Widely regarded as the ‘hidden hand’ behind the revival of psychedelic science in the 21st century, Amanda - through her work at the Beckley Foundation - supported pivotal research into the therapeutic potential of psychedelics and cannabis, enabling critical advancements that have contributed to a global shift in perception around these compounds. She was also a dedicated advocate for compassionate and empirical drug policies, contributing to many public and political discussions that have paved the way for a new era in drug policy and research.
In 2019, she co-founded Beckley Psytech with her son, Cosmo Feilding Mellen, to build upon the Beckley Foundation’s work and pioneer the next generation of treatments for people living with difficult-to-treat mental health conditions.
Cosmo expressed the following: “Amanda was my mother as well as my inspiration and co-founder at Beckley Psytech. I will miss her terribly but I know that she was extremely proud of the work we are doing at Beckley Psytech and I want to pass on my deepest thanks to all of our team members, study participants, and countless other stakeholders who are helping turn Amanda’s vision into reality.”
Marc Wayne, Chairman of Beckley Psytech’s Board of Directors, also said: “Amanda was an extraordinary individual who strongly believed in the power of science to foster greater connection, creativity, and understanding. Her impact on the world of psychedelic science and drug policy cannot be understated and I know that her passion and commitment will live on in the work of Beckley Psytech, the Beckley Foundation, and in all those inspired by her life’s mission. It was my great privilege to work alongside her and I miss her deeply.”
Amanda leaves behind a rich legacy. Her contributions to science and her commitment to a more sensitive, evidence-based approach to public health will continue to inspire individuals and institutions across the globe. At Beckley Psytech, we are deeply grateful for Amanda’s contributions and remain committed to carrying forward her mission of bringing the potential benefits of psychedelic-based treatments into mainstream medical practice.
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
